Anti-Hu CD95 FITC

*Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L, Pintzas A.: Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem. 2005 Jun 17;280 (24) :22856-67. Epub 2005 Mar 8. , URL: https://www.ncbi.nlm.nih.gov/pubmed/15757891?dopt=

*Brumatti G, Yon M, Castro FA, Bueno-da-Silva AE, Jacysyn JF, Brunner T, Amarante-Mendes GP: Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide. Exp Cell Res. 2008 Feb 1;314 (3) :554-63., URL: https://www.ncbi.nlm.nih.gov/pubmed/18078929?ordin, *Guo Z, Zhang M, Tang H, Cao X: Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. Blood. 2005 Sep 15;106 (6) :2033-41., URL: https://www.ncbi.nlm.nih.gov/pubmed/15941911?ordin, *Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PA, Liles WC: Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol. 2003 Jun 15;170 (12) :6209-16., URL: https://www.ncbi.nlm.nih.gov/pubmed/12794152?ordin, *Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998 Mar 16;17 (6) :1675-87., URL: https://www.ncbi.nlm.nih.gov/pubmed/9501089?ordina